The CE-marked and FDA-approved Accu2i pMTA microwave ablation system, which is implanted under the skin, uses single, high-power, high-frequency 2.45 GHz saline-cooled needle for coagulation.

As part of the transaction, AngioDynamics paid $10m in cash as upfront payment, and will pay another $5m in cash at the end of 2013.

AngioDynamics president and CEO Joseph DeVivo said, "With the addition of microwave, we have a complete offering of thermal and non-thermal technologies, further building on our status as a market-leader in the $250 million global tissue ablation market."

AngioDynamics’ products include ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products.